Literature DB >> 9716112

Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus.

J C Crispin1, A Martínez, P de Pablo, C Velasquillo, J Alcocer-Varela.   

Abstract

Accumulating evidence has implicated T cells in the pathogenesis of systemic lupus erythematosus (SLE). The CD69 antigen is an integral membrane protein rapidly induced on the surface of activated lymphocytes. We obtained CD4+ and CD8+ T cells from normal subjects and patients with SLE. The percentage of CD69 expression in freshly isolated cells and after in-vitro incubation with mitogens was quantified by three-colour immunofluorescent staining. Expression of this protein was increased in both CD4+ and CD8+ T-cell subsets from SLE patients when compared with normal cells, although the difference was significant only in the CD8+ T-cell subset (P = 0.05). Cellular activation increased CD69 expression. When stimulated with anti-CD2/CD2R or phytohaemagglutinin (PHA), the percentage and absolute numbers of CD69+ cells were lower in patients than in controls. Addition of anti-interleukin (IL)-10 monoclonal antibody (MoAb) increased the percentage of in-vitro CD69 expression in SLE cells. These results suggest that the peripheral blood lymphocytes from patients with SLE have an intrinsic defect that alters their activation process, including the expression of CD69, and might explain some of the T immunoregulatory abnormalities observed in these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716112     DOI: 10.1046/j.1365-3083.1998.00366.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  14 in total

1.  Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity.

Authors:  José C Crispín; Brendan T Keenan; Michele D Finnell; Bonnie L Bermas; Peter Schur; Elena Massarotti; Elizabeth W Karlson; Lisa M Fitzgerald; Sukran Ergin; Vasileios C Kyttaris; George C Tsokos; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2010-05

2.  Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2) mouse.

Authors:  Malin Sund; Li Li Xu; Arman Rahman; Bi-Feng Qian; Marie-Louise Hammarström; Ake Danielsson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

3.  HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus.

Authors:  J F Viallard; C Bloch-Michel; M Neau-Cransac; J L Taupin; S Garrigue; V Miossec; P Mercie; J L Pellegrin; J F Moreau
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

4.  PPP2R2B hypermethylation causes acquired apoptosis deficiency in systemic autoimmune diseases.

Authors:  Iris K Madera-Salcedo; Beatriz E Sánchez-Hernández; Yevgeniya Svyryd; Marcela Esquivel-Velázquez; Noé Rodríguez-Rodríguez; María Isabel Trejo-Zambrano; H Benjamín García-González; Gabriela Hernández-Molina; Osvaldo M Mutchinick; Jorge Alcocer-Varela; Florencia Rosetti; José C Crispín
Journal:  JCI Insight       Date:  2019-07-23

Review 5.  Interleukin-17 and systemic lupus erythematosus: current concepts.

Authors:  A Nalbandian; J C Crispín; G C Tsokos
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

6.  Identification of systemically expanded activated T cell clones in MRL/lpr and NZB/W F1 lupus model mice.

Authors:  G Zhou; K Fujio; A Sadakata; A Okamoto; R Yu; K Yamamoto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

7.  Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes.

Authors:  Miguel Ascon; Dolores B Ascon; Manchang Liu; Chris Cheadle; Chaitali Sarkar; Lorraine Racusen; Heitham T Hassoun; Hamid Rabb
Journal:  Kidney Int       Date:  2008-12-17       Impact factor: 10.612

8.  Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype.

Authors:  José C Crispín; George C Tsokos
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

Review 9.  CD69: from activation marker to metabolic gatekeeper.

Authors:  Danay Cibrián; Francisco Sánchez-Madrid
Journal:  Eur J Immunol       Date:  2017-06       Impact factor: 5.532

Review 10.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.